Organización Nacional de Trasplantes

Organización Nacional de Trasplantes is Spain’s national transplant organization, headquartered in Madrid and presented in the book as both a national coordinating institution and a participant in the international policy framework surrounding organ donation and transplantation. Its significance lies less in a narrated institutional episode than in the problems it helps frame: a widening gap between transplant demand and organ supply, the need for coordinated allocation strategies, and the ethically difficult question of whether kidneys from hepatitis C virus-positive donors should be used rather than discarded.

Institutional Identity and Setting

Organización Nacional de Trasplantes appears in the transplant literature through its Madrid-based national role. The relevant chapter identifies it as the affiliation of Beatriz Domínguez-Gil, whose work examines renal transplantation from donors with positive serology for hepatitis C. The same institutional setting is associated with a broader Spanish transplant network that includes nephrology teams at Hospital Clinic i Provincial and Hospital 12 de Octubre, linking national coordination with specialist clinical practice.

The organization’s address is given as C/ Sinesio Delgado 6, pavilion 3, in Madrid. This concrete administrative detail places the organization within the infrastructure of a national health system rather than presenting transplantation as an isolated surgical service. Its appearance alongside clinical departments and international transplant bodies reflects a division of labor between coordination, professional expertise, organ procurement, and patient care.

Organ Shortage and Policy Context

The organization is invoked against the background of a global shortage of transplantable organs. At the end of 2009, approximately 63,000 people were on an organ waiting list in the European Union while only 28,000 transplant procedures were performed during that year. The United States faced a comparable imbalance: almost 111,000 people were registered on the waiting list in May 2011, against roughly 28,000 transplant procedures annually. These figures make allocation policy a matter of survival rather than administrative convenience, because many patients deteriorate or die before an organ becomes available.

The shortage also has wider social consequences. The book links unequal access to the growth of organ trafficking and transplant tourism, while noting international calls for greater organ availability and for preventive strategies that reduce diseases treatable by transplantation. In this setting, Organización Nacional de Trasplantes is associated with the effort to move transplantation toward national and international self-sufficiency, a policy goal that requires more than increasing surgical capacity: it requires expanding donation, coordinating institutions, and deciding which medically usable organs should enter the allocation system.

International Coordination and the Positive-Donor Debate

Organización Nacional de Trasplantes is named in the Third WHO Global Consultation on Organ Donation and Transplantation, held in Madrid from March 23 to 25, 2010. The consultation was organized with the World Health Organization and The Transplantation Society and focused on striving toward self-sufficiency in transplantation. Its inclusion in that framework identifies the Spanish organization as a participant in international governance rather than merely a domestic registry or procurement office.

That policy context becomes especially important for kidneys from hepatitis C virus-positive donors. Because hepatitis C virus can be transmitted through organ transplantation, such donors are classified as non-standard-risk donors, and the use of their kidneys remains controversial. Some centers never accept them, while some countries impose technical or legal bans. Yet the number of patients needing transplantation greatly exceeds the supply of donated kidneys, creating a direct institutional question: whether potentially usable kidneys should be rejected because of donor serology or allocated to carefully selected recipients.

Clinical Evidence and Allocation Logic

The chapter associated with Organización Nacional de Trasplantes reviews the safety and efficacy of transplanting kidneys from hepatitis C virus-positive donors into hepatitis C virus-positive recipients. Its evidence base includes center-based and registry-based studies, including long-term experience reported by Jose M. Morales, Josep M. Campistol, Beatriz Domínguez-Gil, Amado Andrés, Nuria Esforzado, and colleagues. The institutional perspective therefore connects policy with observed transplant outcomes rather than treating donor seropositivity as an automatic exclusion.

The clinical decision is shaped by the limited usefulness and substantial burden of antiviral treatment before transplantation. Interferon may cause flu-like symptoms, anemia, neutropenia, depression, and anxiety; treatment can require dose reduction in 35–42% of patients and discontinuation in about 30%. Therapy is prolonged, expensive, not universally accessible, and not uniformly effective. Patients may refuse treatment, fail to respond, or withdraw from it. For some hepatitis C virus RNA-positive patients with end-stage renal disease, remaining on dialysis is expected to be less favorable than transplantation, so a kidney from a hepatitis C virus-positive donor may offer a shorter route to transplantation despite the infectious risk.

The book also describes a structural reason for considering such organs: hepatitis C virus-positive kidneys are increasingly likely to become surplus organs as preventive measures and antiviral treatment reduce the number of infected candidates. In one analysis, these kidneys were 2.60 times more likely to be discarded than hepatitis C virus-negative kidneys. Organización Nacional de Trasplantes therefore stands within a policy problem of avoidable waste. Organizational mechanisms could allow unused organs to be offered across centers, while preemptive transplantation into hepatitis C virus-positive recipients who are not expected to receive interferon could reduce waiting time without imposing the same mismatch between donor status and recipient status.

Relation to the Book’s Governance of Infection

Although the organization is not itself described as a clinical treatment provider, its institutional significance is sharpened by the book’s distinctions among hepatitis C virus exposure, antibody positivity, and active viremia. Diagnosis of chronic infection requires both anti-hepatitis C antibodies and detectable hepatitis C virus RNA, while evaluation of active infection must also consider liver fibrosis and extrahepatic disease. These classifications determine whether a transplant candidate can receive a kidney alone, requires continued surveillance, needs antiviral treatment, or should be referred for simultaneous liver-kidney transplantation.

The same governance logic appears in the management of transplant waiting lists. Candidates who have not previously been tested should undergo antibody screening with nucleic-acid confirmation in low-prevalence settings, or direct nucleic-acid testing in high-prevalence settings. Patients with positive nucleic-acid tests may be placed on hold and referred to a hepatologist. Those who have achieved sustained virological response require at least annual testing to confirm that the response persists, while viremic candidates need regular assessment for progression of liver disease. In this chain of testing, referral, surveillance, and allocation, Organización Nacional de Trasplantes represents the institutional layer that makes clinical categories consequential for access to an organ.

The organization’s place in the book is therefore emblematic of modern transplant medicine: it sits where laboratory classification, waiting-list administration, international policy, and unequal access meet. Its importance is not established through a single dramatic action, but through the practical question it helps organize—how a transplant system can protect recipients from transmissible disease while refusing neither usable organs nor patients whose medical circumstances leave them few alternatives.